Skip to content

COVID-19 Lockdown Related Telemedicine for Type 2 Diabetes

Impact of Telemedicine on Young and Middle-aged Obese Patients With Type 2 Diabetes Mellitus During COVID-19 Pandemic

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04723550
Enrollment
120
Registered
2021-01-25
Start date
2021-01-05
Completion date
2022-01-05
Last updated
2021-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Keywords

Type 2 Diabetes Mellitus, COVID-19 lockdown, Telemedicine, Obesity, Young and middle-aged

Brief summary

At present, in order to cope with the global pandemic of the COVID-19 virus, governments have introduced corresponding measures, COVID-19 lockdown is one of the most important measures. However, lockdown makes the management of chronic diseases (such as type 2 diabetes) more difficult, and telemedicine may be one of the solutions. We hope to explore the effect of telemedicine on blood glucose control and other prognostic indicators of young and middle-aged obese patients with type 2 diabetes who will experience isolation control.

Detailed description

We recruit patients with type 2 diabetes who need to be isolated due to the COVID-19 epidemic, Our study will include young and middle-aged obese patients. The lockdown period is 21 days. The patients will be randomly divided into two groups with a total follow-up time of 6 months. One group is the telemedicine intervention group, and the other group is the routine follow-up control group. The intervention group used the hospital telemedicine management system to upload blood glucose values (fasting and 2h after three meals), food intake of three meals, and exercise volume (Data collection frequency: first three months, 4 times/week; 4-6 Month, 2 times/week).Doctors will collect data from hospital telemedicine management system to guide patients on diets, exercise, and medication adjustments. The control group will be followed up by telephone/outpatient clinic every 1 week. (only telephone follow-up will be conducted during the lockdown period) Then doctors will collect their blood glucose values.(fasting and 2h after three meals) Based on the data collected, The doctors will provide lifestyle guidance to the patients on the telephone or face to face. The clinical data of the two groups of patients will be collected at baseline, 22 days, 3 months, and 6 months respectively. (HbA1c, fasting blood glucose(FBG), blood glucose 2 hours after breakfast, blood pressure, Body Mass Index(BMI), waist-to-hip ratio, total cholesterol(TC), triglyceride(TG), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C), Blood Urea Nitrogen(BUN), serum creatinine(Scr), e-GFR, Self-rating Depression Scale, frequency of hypoglycemia,and Cost effectiveness) The clinical data will be statistically analyzed.

Interventions

DEVICEHospital telemedicine management system

Patients upload data of blood glucose, diet and exercise. Then doctors guide patients' diet, exercise and medication adjustment through the telemedicine system.

OTHERUsual care

Outpatient/telephone follow-up:continued care, as usual, from their primary care provider through out duration of action 6 months intervention period

Sponsors

Wenwen Yin
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Physician diagnosis of Type 2 diabetes for more than 6 months * 7.0%\<HbA1c\<10.0% * Quarantine for 21 days due to COVID-19 outbreak related reasons * age: 18 \ 55 yrs * BMI≥24 * Be able use smart phones and the Internet

Exclusion criteria

* Insulin pump users * For female subjects: pregnancy or lactation, or subject may become pregnant during the study * Patient who underwent obesity surgery to the exclusion of a gastric band, loosened or removed for more than a year * Patients diagnosed with COVID-19 infection * Have severe complications (chronic heart disease, cerebrovascular disease, diagnosed HIV/AIDS, cancer, emphysema, chronic liver or kidney disease) that would affect the subjects' ability to follow the tailored advice

Design outcomes

Primary

MeasureTime frameDescription
Glucose control (HbA1c levels)Baseline, 22days,3 months and 6 monthsChange in HbA1c among control and telemedicine groups from baseline to 6 months

Secondary

MeasureTime frameDescription
Body mass BMI changesBaseline, 22days,3 months and 6 monthsComparison of BMI changes among control and telemedicine groups from baseline to 6 months
Change in biological parameter: BUNBaseline, 22days,3 months and 6 monthsVariation between baseline to 6 months of Biological parameter among control and telemedicine groups: BUN
Change in biological parameter: ScrBaseline, 22days,3 months and 6 monthsVariation between baseline to 6 months of Biological parameter among control and telemedicine groups: Scr
Change in biological parameter: e-GFRBaseline, 22days,3 months and 6 monthsVariation between baseline to 6 months of Biological parameter among control and telemedicine groups: e-GFR
Change in FBGBaseline, 22days,3 months and 6 monthsChange in FBG among control and telemedicine groups from baseline to 6 months
Change in Blood glucose 2 hours after breakfastBaseline, 22days,3 months and 6 monthsChange in Blood glucose 2 hours after breakfast among control and telemedicine groups from baseline to 6 months
Change in Blood pressureBaseline, 22days,3 months and 6 monthsChange in Blood pressure among control and telemedicine groups from baseline to 6 months
Change in biological parameter: TCBaseline, 22days,3 months and 6 monthsVariation between baseline to 6 months of Biological parameter among control and telemedicine groups: TC
Change in waist-to-hip ratio6 monthsComparison of waist-to-hip ratio changes among control and telemedicine groups from baseline to 6 months
Change in biological parameter: TGBaseline, 22days,3 months and 6 monthsVariation between baseline to 6 months of Biological parameter among control and telemedicine groups: TG
Change in biological parameter: HDL-CBaseline, 22days,3 months and 6 monthsVariation between baseline to 6 months of Biological parameter among control and telemedicine groups: HDL-C

Other

MeasureTime frameDescription
Number of hypoglycemia events6 monthsHypoglycemia events for telemedicine group versus control group
Cost effectiveness6 monthsThe objectives are to compare the results of the study in terms of cost and cost-effectiveness of these two strategies
Change in scores measured by Self-rating Depression ScaleBaseline, 22days,3 months and 6 monthsSelf-rating Depression Scale includes 20 items in four dimensions of psychological disorders, namely, psychotic emotional symptoms, somatic disorders, psychomotor disorders, and depression. The maximum value of SDS is 50 points. A lower total score means a better situation in terms of depression and vice versa

Countries

China

Contacts

Primary ContactWenwen Yin, MD.
wenwen261621@163.com+86 18112008016
Backup ContactNing Ding, MD.
961897477@qq.com+86 17712987026

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026